2019 International Congress

Monday, September 23, 2019

1:45pm-3:15pm

Dopaminergic Neuroregeneration in the Diencephalon of 6-OHDA-Lesioned Adult Zebrafish-Based Parkinson’s Disease Model

Y. Vijayanathan, SM. Lim, MP. Tan, FT. Lim, AB. Abdul Majeed, K. Ramasamy (Kuala Lumpur, Malaysia)

Other  ·  Agora 2 West, Level 2

1:45pm-3:15pm

Duloxetine for pain in Parkinsons disease; A single center double blind randomised placebo controlled trial.

S. Azmin, T. Canento, B. Cruse, S. Sung, M. Farrell, A. Evans (Kuala Lumpur, Malaysia)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Duration of rimabotulinumtoxinB action in the treatment of adult sialorrhea

S. Isaacson, M. Lew, F. Pagan, R. Pahwa, D. Chary, T. Clinch (Boca Raton, FL, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Dyadic analysis of the Parkinson’s disease impact on the patient-spouse couple

E. Constant, E. Brugallé, E. Wawrziczny, B. Flinois, K. Dujardin, P. Antoine (Villeneuve D'Ascq, France)

Quality of Life  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Dynamics of Device-based Treatments for Parkinson´s Disease in Germany from 2010 – 2017

L. Tönges, D. Bartig, C. Krogias, D. Richter (Bochum, Germany)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Dysphagia in Adults with Niemann-Pick Disease Type C

C. Lewis, M. Walterfang, A. Vogel (Melbourne, Australia)

Rare Genetic and Metabolic Diseases  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Dystonia as a main clinical feature of AAMR with a novel GMPPA mutation:A case report

SL. Li, H. Wang, L. Wang, Y. Guo, XH. Wan, HP. Li, JY. Shi (Peking, China)

Rare Genetic and Metabolic Diseases  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Early onset parkinsonism and optic atrophy due to SLC25A46 mutations

G. Bitetto, MC. Malaguti, E. Monfrini, A. Di Fonzo (Milan, Italy)

Genetics  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Effect of 8-Weeks Treadmill Training on Selected Gait Parameters and Quality of Life of Patients with Parkinson’s Disease

A. Ogundele, M. Olaogun, M. Komolafe (Ile Ife, Nigeria)

Physical and Occupational Therapy  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Effect of an Increase in Dose of Istradefylline, an A2A Receptor Antagonist, in Levodopa (LD)-Treated Patients with Parkinson’s Disease (PD)

N. Hattori, T. Nomura, P. Salzman, H. Kitabayashi, M. Ishiuchi, K. Toyama, A. Mori (Tokyo, Japan)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3